This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ogihara, T. Articles by Rakugi, H. Search for Related Content PubMed PubMed Citation Articles by Ogihara, T. Articles by Rakugi, H. Social Bookmarking                         What's this?

Which strategy in inhibition of the renin-angiotensin system is the most efficient for heart failure?

Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

Hiromi Rakugi

Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

References

• Brunner HR, Laragh JH, Baer L. et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-9.[Web of Science][Medline] [Order article via Infotrieve]
• Brunner HR, Sealey JE, Laragh JH Renin as a risk factor in essential hypertension: more evidence. Am J Med 1973;55:295-302.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121: 1244-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.[Abstract]
• McMurray JJ, Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362: 767-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• McMurray J., Pitt B., Latini R. et al. Effects of the oral direct inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.[Abstract/Free Full Text]
• Parving HH, Persson F., Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46.[Abstract/Free Full Text]
• Yusuf S., Teo KK, Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 9, No. 3, 184-185 (2008)
DOI: 10.1177/1470320308097418


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ogihara, T. Articles by Rakugi, H. Search for Related Content PubMed PubMed Citation Articles by Ogihara, T. Articles by Rakugi, H. Social Bookmarking                         What's this?